Compare Bristol-Myers Squibb Co (BMY) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Sezzle Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.61 (market cap $116.30B), while Sezzle Inc trades at $188.98 (market cap $6.15B). The key difference: Bristol-Myers Squibb Co is far larger — about 18.9× Sezzle Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| BMY | SEZL | |
|---|---|---|
Market Cap | $116.30B | $6.15B |
Sector | Health | Technology |
52-Week High | $62.37 | $183.24 |
52-Week Low | $42.60 | $50.97 |
Enterprise Value | $152.24B | $6.18B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SEZL trades at $160.25, down 10.66% over the last session, but maintains a bullish technical outlook with support at $156 and resistance at $165. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.43, and raised full-year guidance. Revenue growth accelerated to 29% year-over-year, with net income margin expanding to 30.83%.
Outlook remains positive given consistent earnings beats and product expansion, though high valuation multiples (P/E 43.68) and a recent securities law investigation pose risks. Analyst consensus is split evenly between Buy and Hold, with a $162 price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
